Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Thymosin Beta 4

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Thymosin Beta 4 Research Leads Toward Potential Future Anti-aging Therapy
    Thymosin Beta 4 Research Leads Toward Potential Future Anti-aging Therapy

    31 Jan 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/thymosin-beta-4-research-leads-toward-potential-future-anti-aging-therapy-301734403.html

    PR NEWSWIRE
    31 Jan 2023
    Share Share
    New Research Demonstrates Thymosin Beta 4's Potential Positive Effects
    New Research Demonstrates Thymosin Beta 4's Potential Positive Effects

    05 Oct 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/new-research-demonstrates-thymosin-beta-4s-potential-positive--effects-on-alzheimers-disease-301392841.html

    PRNEWSWIRE
    05 Oct 2021
    Share Share
    Tailor Made Compounding (Sterile Drug Manufacturer) Receives FDA Form 483
    Tailor Made Compounding (Sterile Drug Manufacturer) Receives FDA Form 483

    30 Oct 2018

    // FDA

    https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-afda-orgs/documents/document/ucm627650.pdf

    FDA
    30 Oct 2018
    Share Share